Doji (W) on both stocks
Fundamentals are terrific:
Forward cash and equivalents make those stocks nearly free ( pipeline, production capacity, distribution networks priced at 0) :
- most contracts for 22 are already signed and/or partly cashed in (US still negotiating for MRNA),
- contracts signing for 23 has started as well as governments have to be ready ( access to the doses) in case of new Covid waves
- MRNA is developing a new concept (2 MOU signed) that i d call PAAS for biotech ( government would be entering into a 10 years agreement in exchange for benefiting of their own capacity and modularity of vaccines development and production). The point being like for SAAS and PAAS in IT pricing model would be recurring.
So fantastic defensive stocks in the current environment ( favoring cash, dividend and real assets ) and then we might get lucky as well !